title: Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
abstract: OBJECTIVE
  Sulfonylureas block the activation of vascular potassium-dependent ATP channels and impair the vasodilating response to ischcmia in nondiabetic individuals, but it is not know whether this occurs in type 2 diabetic patients under chronic treatment with these drugs. Glimepiride, a new sulfonylurea, apparently has no cardiovascular interactions. The aim of our study was to compare the effect of the widely used compound glibenclamide, the pancreas-specific glimepiride, and diet treatment alone on brachial artery response to acute forearm ischemia.
  
  
  METHODS
  Brachial artery examination was performed by a high-resolution ultrasound technique on 20 type 2 diabetic patients aged mean +/- SD) 67 +/- 2 years and on 18 nondiabetic patients matched for age, hypertension, and dislipidemia. Diabetic subjects underwent three separate evaluations at the end of each 8-week treatment period, during which they received glibenclamide, glimepiride, or diet alone according to crossover design. Scans were obtained before and after 4.5 min of forearm ischemia. Postischemic vasodilation and hyperemia were expressed as percent variations in vessel diameter and blood flow.
  
  
  RESULTS
  Postischemic vasodilation and hyperemia were, respectively, 5.42 +/- 0.90 and 331 +/- 38% during glibenclamide, 5.46 +/- 0.69 and 326 +/- 28% during glimepiride, and 5.17 +/- 0.64 and 357 +/- 35% during diet treatment (NS). These results were similar to those found in the nondiabetic patients (6.44 +/- 0.68 and 406 +/- 42%, NS).
  
  
  CONCLUSIONS
  In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes.
authors.affiliation: Department of Internal Medicine, University of Genova,  Italy.
authors.forename: P
authors.initials: P
authors.lastname: Spallarossa
authors.forename: M
authors.initials: M
authors.lastname: Schiavo
authors.forename: P
authors.initials: P
authors.lastname: Rossettin
authors.forename: S
authors.initials: S
authors.lastname: Cordone
authors.forename: L
authors.initials: L
authors.lastname: Olivotti
authors.forename: R
authors.initials: R
authors.lastname: Cordera
authors.forename: C
authors.initials: C
authors.lastname: Brunelli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000502:physiology / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology*; D003927:Diet, Diabetic; D005260:Female; D005542:Forearm / Q000098:blood supply; D005907:Gliclazide / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000503:physiopathology; D006973:Hypertension / Q000150:complications / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007511:Ischemia / Q000503:physiopathology*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014463:Ultrasonography
chemical_list: D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D008687:Metformin; D005907:Gliclazide; D005905:Glyburide